keyword
https://read.qxmd.com/read/38627942/muscular-function-recovery-from-general-anesthesia-in-132-patients-undergoing-surgery-with-acceleromyography-combined-acceleromyography-and-ultrasonography-and-without-monitoring-muscular-function
#21
JOURNAL ARTICLE
Shiqian Huang, Yu Pan, Yu Wang, Shuaijie Pei, Xiang Wang, Shujun Sun, Shanglong Yao, Xiangdong Chen, Haifa Xia
BACKGROUND Diaphragmatic thickness fraction (DTF), measured by ultrasound, can predict the occurrence of postoperative residual neuromuscular blockade (RNMB). We hypothesized that the utilization of diaphragmatic ultrasound during the postoperative awakening phase of anesthesia in patients offers a successful means of avoiding RNMB in a notably comfortable manner, as compared to the use of acceleromyograph. MATERIAL AND METHODS Patients who underwent elective thyroid cancer radical surgery were enrolled in this prospective clinical study...
April 17, 2024: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://read.qxmd.com/read/38627238/derazantinib-alone-and-with-atezolizumab-in-metastatic-urothelial-carcinoma-with-activating-fgfr-aberrations
#22
JOURNAL ARTICLE
Andrea Necchi, Rodryg Ramlau, Alejandro Falcón González, Arvind Chaudhry, Tilman Todenhöfer, Rana Tahbaz, Elisa Fontana, Patrizia Giannatempo, Jean-Laurent Deville, Damien Pouessel, Shinkyo Yoon, Thomas Powles, Mathieu Bernat, Manuel Häckl, Michalina Marszewska, Phil McKernan, Mikael Saulay, Federica Scaleia, Marc Engelhardt, Yohann Loriot, Arlene Siefker-Radtke, Maria De Santis
BACKGROUND: This Phase 1 b/2 study assessed the efficacy, in terms of objective response rate (ORR) of the FGFR1/2/3 kinase inhibitor derazantinib as monotherapy or in combination with atezolizumab in patients with metastatic urothelial cancer (mUC) and FGFR1-3 genetic aberrations (FGFR1-3GA). METHODS: This multicenter, open-label study comprised 5 substudies. In Substudies 1 and 5, patients with mUC with FGFR1-3GA received derazantinib monotherapy (300 mg QD in Substudy 1, 200 mg BID in Substudy 5)...
April 16, 2024: JNCI Cancer Spectrum
https://read.qxmd.com/read/38626793/clinical-risks-for-chronic-lymphocytic-leukemia
#23
REVIEW
Jennifer R Brown
Our understanding of risk factors for the development of chronic lymphocytic leukemia (CLL) is still incomplete and includes genetic and environmental factors. CLL is one of the most familial of all cancers, yet common high-penetrance risk alleles have not been identified. Genome-wide association studies have identified many common variants with low relative risks, whereas exome-wide rare variant analysis has implicated ATM in CLL causation. Environmental factors have also been challenging to identify given the limited understanding of the relevant time period of exposure relative to diagnosis, and the inability to quantify past exposures...
April 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38626709/long-term-follow-up-and-exploratory-analysis-of-lenvatinib-in-patients-with-metastatic-or-recurrent-thymic-carcinoma-results-from-the-multicenter-phase-2-remora-trial
#24
JOURNAL ARTICLE
Seiji Niho, Jun Sato, Miyako Satouchi, Shoichi Itoh, Yusuke Okuma, Hidenori Mizugaki, Haruyasu Murakami, Yasuhito Fujisaka, Toshiyuki Kozuki, Kenichi Nakamura, Ryunosuke Machida, Yuichiro Ohe, Toshiyuki Tamai, Hiroki Ikezawa, Noboru Yamamoto
OBJECTIVES: The main objective of this report was to detail the long-term follow-up data from the REMORA study, which investigated the safety and efficacy of lenvatinib in patients with thymic carcinoma. In addition, an exploratory analysis of the association between relative dose intensity (RDI) and the efficacy of lenvatinib is presented. MATERIALS AND METHODS: The single-arm, open-label, phase 2 REMORA study was conducted at eight Japanese institutions. Forty-two patients received oral lenvatinib 24 mg once daily in 4-week cycles until the occurrence of intolerable adverse events or disease progression...
March 30, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38626290/data-preprocessing-techniques-for-artificial-learning-ai-machine-learning-ml-readiness-systematic-review-of-wearable-sensor-data-in-cancer-care
#25
JOURNAL ARTICLE
Bengie L Ortiz
BACKGROUND: Wearable sensors are increasingly being explored in healthcare, including in cancer care, for their potential in continuously monitoring patients. Despite their growing adoption, significant challenges remain in the quality and consistency of data collected from wearable sensors. In particular, preprocessing pipelines to clean and standardize raw data have not been fully optimized. OBJECTIVE: The aim of this study was to conduct a systematic review of preprocessing techniques employed on wearable sensor data to ensure their readiness for artificial intelligence/machine learning ("AI/ML-ready") applications...
April 16, 2024: JMIR MHealth and UHealth
https://read.qxmd.com/read/38625787/physical-activity-levels-and-factors-affecting-them-in-hospitalized-children-with-leukemia
#26
JOURNAL ARTICLE
Yuru Huang, Xiaofen Zheng, Qianhe Chen, Kaiyao Jiang, Afen Zheng, Liya Jin, Runping Wang, Jun Chen, Ping Zou, Chunmei Zhang
BACKGROUND: Physical activity promotes healthy physical and mental development in children with leukemia. However, the level of physical activity in hospitalized children with leukemia and the factors that influence it are unknown. OBJECTIVES: The aims of this study were to understand the physical activity level of hospitalized children with leukemia and to explore the factors influencing it to provide a reference for physical activity assessment and intervention in such children...
April 12, 2024: Cancer Nursing
https://read.qxmd.com/read/38625786/human-caring-perspectives-of-care-meanings-and-expressions-in-a-nigerian-cancer-care-setting
#27
JOURNAL ARTICLE
Chinomso Nwozichi, Mary Dioise Ramos, Kawther Hamash, Ayodeji O Ogunmuyiwa, Oluwaseun D Martins-Akinlose, Mosidat Olabisi Bakare, Margaret Olutosin Ojewale
BACKGROUND: Caring in Africa is often viewed from sociopolitical and humanity perspectives. OBJECTIVE: The aim of this study was to investigate the meanings and expressions of caring from the narratives of persons living with cancer and their nurses. METHODS: This study adopted a qualitative ethnonursing methodology. A purposive sampling technique was used to select the key participants, who were grouped into 7 nurses and 6 patients. General participants included 4 physicians, 3 ward assistants, and 6 patients' relatives...
April 12, 2024: Cancer Nursing
https://read.qxmd.com/read/38625698/neoadjuvant-chemo-immunotherapy-for-early-stage-non-small-cell-lung-cancer-a-systematic-review-and-meta-analysis
#28
JOURNAL ARTICLE
Giuseppe Luigi Banna, Mona Ali Hassan, Alessio Signori, Emilio Francesco Giunta, Akash Maniam, Shobana Anpalakhan, Shyamika Acharige, Aruni Ghose, Alfredo Addeo
IMPORTANCE: Randomized clinical trials (RCTs) with neoadjuvant immune checkpoint inhibitors (ICIs) plus chemotherapy (ICI-chemotherapy) for patients with early-stage non-small cell lung cancer (NSCLC) have reported consistent associations with event-free survival (EFS) and pathologic complete response (pCR) pending longer follow-up for overall survival data. OBJECTIVE: To assess the pooled benefit of ICI-chemotherapy in 2-year EFS and pCR among patients with NSCLC and examine the impact of clinical, pathologic, and treatment-related factors...
April 1, 2024: JAMA Network Open
https://read.qxmd.com/read/38625495/comparison-of-efficacy-and-safety-of-pd-1-pd-l1-combination-therapy-in-first-line-treatment-of-advanced-nsclc-an-updated-systematic-review-and-network-meta-analysis
#29
JOURNAL ARTICLE
Yanqing Yang, Wei Chen, Lixian Dong, Lian Duan, Pengfei Gao
BACKGROUND: The use of immune checkpoint inhibitors has led to an increase in randomized controlled trials exploring various first-line combination treatment regimens. With the introduction of new PD-1/PD-L1 inhibitors, there are now more clinical options available. For the first time, the AK105 monoclonal antibody Penpulimab, developed in China, was included. The AK105-302 Phase III trial studied the efficacy and safety of Penpulimab combined with chemotherapy in patients with advanced or metastatic squamous NSCLC...
April 16, 2024: Clinical & Translational Oncology
https://read.qxmd.com/read/38625476/phase-i-ii-study-of-stereotactic-body-radiotherapy-boost-in-patients-with-cervical-cancer-ineligible-for-intracavitary-brachytherapy
#30
JOURNAL ARTICLE
Kei Ito, Yujiro Nakajima, Hiroaki Ogawa, Akiko Furusawa, Keiko Nemoto Murofushi, Satoshi Kito, Nao Kino, Toshiharu Yasugi, Takashi Uno, Katsuyuki Karasawa
PURPOSE: Stereotactic body radiotherapy (SBRT) boost is a promising treatment for cervical cancer patients who are ineligible for intracavitary brachytherapy (ICBT). The aim of this multicenter, single-arm, phase I/II study was to prospectively evaluate the efficacy and toxicity of SBRT boost. MATERIALS AND METHODS: ICBT-ineligible patients with untreated cervical cancer were enrolled. Patients underwent whole-pelvic radiotherapy (45 Gy in 25 fractions) with SBRT boost to the primary lesion...
April 16, 2024: Japanese Journal of Radiology
https://read.qxmd.com/read/38623919/donor-preactivation-based-glycan-assembly-from-manual-to-automated-synthesis
#31
JOURNAL ARTICLE
Wenlong Yao, Xin-Shan Ye
ConspectusCarbohydrates are called the third chain of life. Carbohydrates participate in many important biochemical functions in living species, and the biological information carried by them is several orders of magnitude larger than that of nucleic acids and proteins. However, due to the intrinsic complexity and heterogeneity of carbohydrate structures, furnishing pure and structurally well-defined glycans for functional studies is a formidable task, especially for homogeneous large-size glycans. To address this issue, we have developed a donor preactivation-based one-pot glycosylation strategy enabling multiple sequential glycosylations in a single reaction vessel...
April 15, 2024: Accounts of Chemical Research
https://read.qxmd.com/read/38623624/robust-high-performance-thin-layer-chromatography-hptlc-method-for-stability-assessment-and-simultaneous-quantification-of-epigallocatechin-3-gallate-and-rosmarinic-acid-in-lipid-based-nanoparticles-and-biological-matrices
#32
JOURNAL ARTICLE
Rahul Koli, Vinod S Mannur, Priya P Shetti
INTRODUCTION: Skin cancer poses a significant health risk globally, necessitating effective and safe therapeutic interventions. Epigallocatechin-3-gallate (EGCG) from green tea and rosmarinic acid (RA) from herbs like rosemary offer promising anticancer properties. Combining these compounds may enhance their effectiveness, prompting the need for a reliable analytical method to quantify them. OBJECTIVE: Herein, we present the development and validation of a high-performance thin-layer chromatography (HPTLC) method for concurrent quantification of EGCG and RA in lipid-based nanoparticles and biological samples...
April 16, 2024: Phytochemical Analysis: PCA
https://read.qxmd.com/read/38622840/health-related-quality-of-life-in-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-treated-with-daratumumab-lenalidomide-bortezomib-and-dexamethasone-patient-reported-outcomes-from-griffin
#33
JOURNAL ARTICLE
Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Robert Z Orlowski, Kenneth H Shain, Andrew J Cowan, Katharine S Gries, Huiling Pei, Annelore Cortoos, Sharmila Patel, Thomas S Lin, Peter M Voorhees, Saad Z Usmani, Paul G Richardson
In the phase 2 GRIFFIN trial (ClinicalTrials.gov identifier: NCT02874742), daratumumab added to lenalidomide, bortezomib, and dexamethasone (D-RVd) improved depth of response and progression-free survival (PFS) versus lenalidomide, bortezomib, and dexamethasone (RVd) alone in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient-reported outcomes (PROs) collected using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30-item (QLQ-C30), EORTC Quality of Life Questionnaire Multiple Myeloma Module 20-item (QLQ-MY20), and EuroQol 5-Dimension 5-Level (EQ-5D-5L) tools on day 1 of cycles 1, 2, and 3; on day 21 of cycle 4 (end of induction therapy); on day 1 of cycle 5; on day 21 of cycle 6 (end of posttransplant consolidation therapy); and at months 6, 12, 18, and 24 of maintenance therapy...
April 15, 2024: American Journal of Hematology
https://read.qxmd.com/read/38621793/upadacitinib-in-rheumatoid-arthritis-and-inadequate-response-to-conventional-synthetic-disease-modifying-antirheumatic-drugs-efficacy-and-safety-through-5-years-select-next
#34
JOURNAL ARTICLE
Gerd R Burmester, Filip Van den Bosch, John Tesser, Anna Shmagel, Yanxi Liu, Nasser Khan, Heidi S Camp, Alan Kivitz
OBJECTIVE: To report 5-year efficacy and safety of upadacitinib in rheumatoid arthritis (RA) from the phase 3 long-term extension (LTE) of SELECT-NEXT. METHODS: Patients on stable conventional synthetic disease-modifying antirheumatic drugs were randomized to upadacitinib 15 mg, upadacitinib 30 mg once daily (UPA15/30), or placebo for 12 weeks. Following this, placebo-randomized patients were switched to UPA15 or UPA30 in the LTE; upadacitinib-randomized patients continued their original dose...
April 15, 2024: Journal of Rheumatology
https://read.qxmd.com/read/38621400/-177-lu-lu-psma-617-plus-enzalutamide-in-patients-with-metastatic-castration-resistant-prostate-cancer-enza-p-an-open-label-multicentre-randomised-phase-2-trial
#35
JOURNAL ARTICLE
Louise Emmett, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M Joshua, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J Francis, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Craig Gedye, Natalie K Rutherford, Shahneen Sandhu, Aravind Ravi Kumar, David Pook, Shakher Ramdave, David P Nadebaum, Mark Voskoboynik, Andrew D Redfern, William Macdonald, Laurence Krieger, Geoff Schembri, Wei Chua, Peter Lin, Lisa Horvath, Patricia Bastick, Patrick Butler, Alison Yan Zhang, Sonia Yip, Hayley Thomas, Ailsa Langford, Michael S Hofman, Margaret McJannett, Andrew James Martin, Martin R Stockler, Ian D Davis
BACKGROUND: Enzalutamide and lutetium-177 [177 Lu]Lu-prostate-specific membrane antigen (PSMA)-617 both improve overall survival in patients with metastatic castration-resistant prostate cancer. Androgen and PSMA receptors have a close intracellular relationship, with data suggesting complementary benefit if targeted concurrently. In this study, we assessed the activity and safety of enzalutamide plus adaptive-dosed [177 Lu]Lu-PSMA-617 versus enzalutamide alone as first-line treatment for metastatic castration-resistant prostate cancer...
April 12, 2024: Lancet Oncology
https://read.qxmd.com/read/38620056/prophylactic-use-of-biologic-mesh-in-ileal-conduit-pubmic-a-randomized-clinical-trial
#36
JOURNAL ARTICLE
Hooman Djaladat, Alireza Ghoreifi, Tapas Tejura, Gus Miranda, Jie Cai, Farshad Sheybaee Moghaddam, Ileana Aldana, Rene Sotelo, Inderbir Gill, Sumeet Bhanvadia, Anne Schuckman, Mihir Desai, Monish Aron, Siamak Daneshmand, Vinay Duddalwar
PURPOSE: We assessed the effect of prophylactic biologic mesh on parastomal hernia (PSH) development in patients undergoing cystectomy and ileal conduit (IC). MATERIALS AND METHODS: This phase 3, randomized, controlled trial (NCT02439060) included 146 patients who underwent cystectomy and IC at the University of Southern California between 2015 and 2021. Follow-ups were physical exam and CT every 4 to 6 months up to 2 years. Patients were randomized 1:1 to receive FlexHD prophylactic biological mesh using sublay intraperitoneal technique vs standard IC...
April 15, 2024: Journal of Urology
https://read.qxmd.com/read/38618710/cytotoxic-activity-and-cell-specificity-of-a-novel-lhrh-peptide-drug-conjugate-d-cys6-lhrh-vedotin-against-ovarian-cancer-cell-lines
#37
JOURNAL ARTICLE
Subramanyam Vankadara, Zhiyuan Ke, Sifang Wang, Sin Yun Foo, Jayantha Gunaratne, May Ann Lee, Xiaoying Koh, C S Brian Chia
Ovarian cancer is the most deadly female gynaecological malignancy in developed countries and new treatments are urgently needed. The luteinising hormone releasing hormone (LHRH) peptide drug conjugate Zoptarelin doxorubicin is one such potential new drug modality that entered clinical trials for treating LHRH receptor-positive gynaecological cancers. However, development stopped after disappointing Phase 3 results in 2017. We believe the lack of efficacy was due to linker instability and payload potency. In this work, we replaced its linker-toxin with vedotin (MC-VC-PABC-MMAE), yielding the novel peptide drug conjugate D-Cys6-LHRH vedotin...
April 2024: Chemical Biology & Drug Design
https://read.qxmd.com/read/38618335/effectiveness-of-a-health-educational-program-in-enhancing-breast-cancer-knowledge-among-women-in-rural-karnataka-south-india
#38
JOURNAL ARTICLE
Mainaz Mainaz, Mohammed Guthigar, Poonam Naik
INTRODUCTION AND AIM: Breast cancer is one of the significant causes of mortality in India, ranking second only to cervical cancer among women. Annually, the country has witnessed the detection of 200,000 new cases, with 60% identified in the early stages. This study aimed to assess the effectiveness of a health education intervention program designed to enhance knowledge about breast cancer among women in rural Karnataka. MATERIALS AND METHODS: A descriptive study design was employed and a total of 320 women were selected through multi-stage sampling...
March 2024: Curēus
https://read.qxmd.com/read/38618203/camrelizumab-chemotherapy-and-apatinib-in-the-neoadjuvant-treatment-of-resectable-oesophageal-squamous-cell-carcinoma-a-single-arm-phase-2-trial
#39
JOURNAL ARTICLE
Zixiang Wu, Chuanqiang Wu, Jing Zhao, Cong Wu, Haixian Peng, Qi Wang, Rui Bai, Xuefeng Fang, Hong He, Hong Shen, Ming Wu
BACKGROUND: In resectable oesophageal squamous cell carcinoma (ESCC), the efficacy of camrelizumab combined with chemotherapy and apatinib followed by minimally invasive oesophagectomy is not clear. We aimed to fill this knowledge gap. METHODS: This investigator-initiated, single-arm, prospective, phase 2 trial was performed at the Second Affiliated Hospital of Zhejiang University, China. Patients (aged 18-75 years) who were histologically or cytologically diagnosed with ESCC were deemed suitable to participate in this trial...
May 2024: EClinicalMedicine
https://read.qxmd.com/read/38617773/comparison-of-early-postoperative-pulmonary-complications-between-two-lung-ventilation-with-artificial-pneumothorax-and-one-lung-ventilation-with-bronchial-blockade-in-patients-undergoing-minimally-invasive-esophagectomy-a-retrospective-propensity-score-matched
#40
JOURNAL ARTICLE
Xiaoxi Li, Ling Yu, Jiaonan Yang, Miao Fu, Hongyu Tan
BACKGROUND: Two-lung ventilation (TLV) with artificial carbon dioxide (CO2 ) pneumothorax is used during the thoracoscopic phase of minimally invasive esophagectomy (MIE). However, the impact of TLV with artificial pneumothorax on postoperative pulmonary complications (PPCs) after MIE is unclear. This study aimed to compare the incidence of early PPCs between TLV with CO2 pneumothorax and one-lung ventilation (OLV) with bronchial blockade in patients undergoing MIE. METHODS: Five hundred ninety-three patients with esophageal cancer who underwent elective MIE with two-field lymph node dissection were analyzed...
March 29, 2024: Journal of Thoracic Disease
keyword
keyword
17437
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.